Viking Therapeutics, Inc.
VKTX
$23.94
$0.341.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -42.01% | -12.09% | 18.67% | -11.18% | -9.19% |
| Total Depreciation and Amortization | 26.44% | 16.00% | 1.35% | 0.00% | 1.37% |
| Total Amortization of Deferred Charges | 0.00% | 33.33% | -35.71% | 7.69% | 1,200.00% |
| Total Other Non-Cash Items | -57.78% | 135.30% | -67.94% | 272.41% | 3.12% |
| Change in Net Operating Assets | 337.98% | 87.12% | -150.24% | 191.24% | 276.43% |
| Cash from Operations | -41.98% | 22.98% | -364.84% | 65.23% | 10.27% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -74.58% | 120.55% | 72.58% | -1,386.74% | 385.09% |
| Cash from Investing | -74.58% | 120.55% | 72.58% | -1,386.74% | 385.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -60.35% | -13.18% | -99.55% | 344,654.26% | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -60.35% | -13.18% | -99.52% | 322,260.11% | 354.05% |
| Foreign Exchange rate Adjustments | -155.17% | -1,066.67% | 106.25% | -196.00% | 173.53% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -468.02% | 104.24% | -208.28% | 664.08% | 156.69% |